前不久的上海"十四五"规划成果系列新闻发布会上，闵行区发布的"生产总值突破4000亿元，财政 总收入突破900亿元，总量均位居全市第二"等数据令人振奋。记者还注意到闵行区领导开场的第一句话 ——"闵行区地处上海地理中心，是连接长三角的桥头堡、沟通全球的重要枢纽门户"。 或许，正是这种"站C位"的目标，激励闵行多年来一直在各领域用力拼搏、奋勇争先。 舍得"大手笔" 在闵行"十四五"成绩单中，我们还看到了另一个抢眼数据——"闵行全区全社会研发经费支出占 GDP比重达8%左右，保持全市首位"。这不是某一年的努力，而是多年来始终舍得大手笔投入。 闵行正为地区发展积蓄"长期领跑"的强大动能。据统计，"十四五"期间，闵行荣获13项国家科学技 术奖、210项（人）上海市科学技术奖；培育国家级专精特新"小巨人"企业119家、市级及以上专精特新 企业1665家，数量全市领先。 记者 黄勇娣 前不久，"海聚英才"创业城在闵行揭牌，将通过"空间使用零成本、安居乐活零负担、专业服务零 距离、资源对接零障碍、事务帮办零等待"的支撑体系，让人才创业无忧，让每个创意找到生长沃土。 闵行区全力推动产业迭代升级，积极构建现代化产业体系，已形成 ...

Summary of the Conference Call for Sanbo Brain Science Company Overview - **Company**: Sanbo Brain Science - **Industry**: Healthcare, specifically focusing on brain-machine interface technology and neurosurgery Key Points and Arguments Financial Performance - **Revenue Stability**: Revenue for the first half of the year remained flat compared to the previous year, with growth observed in Beijing, Henan, and Fujian regions, while Kunming faced challenges due to relocation [2][3] - **Profit Growth**: Expected single-digit profit growth attributed to supply chain optimization and contributions from newly acquired hospitals, with the Chengdu hospital maintaining positive profitability [2][3] Technological Advancements - **Clinical Trials**: Successful completion of an interventional brain-machine interface trial in Fujian, with plans for another trial in Beijing [2][5] - **Research Collaboration**: Joint research projects with universities focusing on early-stage technology research for epilepsy and Parkinson's disease, with minimal fees charged [10][11] New Hospital Developments - **New Facilities**: Progress on new hospital locations, with the Beijing facility expected to relocate in Q1 2025, and the Kunming facility now operational after relocation [2][6] Industry Challenges - **Impact of DRG Payment System**: The implementation of the DRG (Diagnosis-Related Group) payment system has led to a decrease in inpatient costs by approximately 10%, necessitating an increase in patient volume to offset revenue losses [4][16] - **Market Dynamics**: A shift in patient preferences towards pharmacies and clinics due to perceived cost-effectiveness, impacting hospital visit numbers [16] Future Growth Strategies - **M&A Fund**: Establishment of a 300 million yuan merger and acquisition fund aimed at acquiring and incubating hospitals, with contributions from the company, local governments, and large pharmaceutical companies [4][13] - **Expansion Plans**: Plans to expand into the Yangtze River Delta and Pearl River Delta regions through acquisitions, with a focus on enhancing operational efficiency and service quality [16][17] Clinical Application of Brain-Machine Interface Technology - **Current Status**: The technology is in the early clinical validation stage, primarily focused on experimental verification, with applications in neuro-regulation for conditions like Parkinson's disease and epilepsy [7][9] Talent Acquisition and Incentives - **Attracting Talent**: The hospital offers flexible mechanisms and equity incentives to attract core experts, providing significant career advancement opportunities compared to traditional public hospitals [18][19] Collaboration with Universities - **Resource Utilization**: Collaboration with universities to leverage resources for research and teaching, ensuring high-quality support for clinical and academic endeavors [20] Financial Management of Acquisitions - **Risk Management**: Contracts for new acquisitions include provisions for potential risks such as Medicare deductions and legal disputes, ensuring effective management of hidden liabilities [26] Additional Important Information - **AI Integration**: Current clinical and management operations have not fully integrated AI models, with a cautious approach towards evaluating the effectiveness of such technologies [22][23] - **Patient Volume Trends**: Observations indicate a decline in hospital visits, with a notable increase in business for clinics and pharmacies [16][24] This summary encapsulates the key insights from the conference call, highlighting the company's performance, strategic initiatives, and industry challenges.